SequelSEC

SERA PROGNOSTICS, INC. SERA

Services-Medical Laboratories · CIK 0001534969 · Fiscal year ends 1231

Revenue
$81.00K
Fiscal year ended 2025-12-31
Operating income
-$36.50M
Fiscal year ended 2025-12-31
Free cash flow
-$26.35M
Fiscal year ended 2025-12-31

SERA PROGNOSTICS, INC. (SERA) reported revenue of $81.00K and net income of -$31.93M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from SERA PROGNOSTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

SERA PROGNOSTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$81.00K$77.00K$306.00K$268.00K$82.00K$25.00K
Cost of revenue$164.00K$82.00K$210.00KUnavailableUnavailableUnavailable
Gross profit-$83.00K-$5.00K$96.00KUnavailableUnavailableUnavailable
Operating income-$36.50M-$36.64M-$39.82M-$45.65M-$35.40M-$17.97M
Net income-$31.93M-$32.90M-$36.24M-$44.19M-$35.01M-$19.85M
Research & development$13.17M$14.73M$15.22M$14.24M$11.02M$7.78M
Weighted-average diluted sharesshares 47.66Mshares 33.16Mshares 31.20Mshares 30.94Mshares 15.00Mshares 1.56M
Pretax income-$31.93M-$32.90MUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0
Diluted EPS$-0.67$-0.99$-1.16$-1.43$-2.33$-12.76
Selling, general & administrative$23.25M$21.90M$24.69M$31.48M$24.42M$10.20M
General & administrative$16.70M$16.13M$16.34M$16.78M$14.09M$6.56M
Selling & marketing$6.55M$5.77M$8.35M$14.70M$10.33M$3.64M

Balance

SERA PROGNOSTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$3.94M$4.04M$3.88M$29.88M$58.93M$13.53M
Total assets$101.93M$72.58M$95.44M$116.33M$147.03M$14.80M
Current assets$40.77M$47.60M$61.34M$90.12M$110.25M$13.73M
Total liabilities$26.52M$24.77M$25.28M$17.39M$8.46M$12.33M
Current liabilities$24.19M$24.77M$24.44M$15.54M$8.41M$11.24M
Total equity incl. NCI$75.41M$47.80M$70.16M$98.94M$138.56M-$125.57M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$12.00K$34.00K$160.00K$113.00K$27.00K$2.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$862.00K$1.97M$1.05M$1.55M$1.20M$441.00K

Cash flow

SERA PROGNOSTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$25.62M-$14.19M-$27.19M-$34.61M-$31.64M-$16.87M
Capital expenditures$726.00K$56.00K$128.00K$791.00K$1.30M$149.00K
Investing cash flow-$28.50M$11.74M$438.00K$5.55M-$82.56M-$149.00K
Financing cash flow$54.03M$2.61M$752.00K$5.00K$159.59M$9.16M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$5.11M$7.01M$5.27M$5.06M$3.13M$726.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$940.00K$833.00K$900.00K$756.00K$659.00K$895.00K

Derived

SERA PROGNOSTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$26.35M-$14.24M-$27.32M-$35.40M-$32.94M-$17.02M
Gross margin-102.5%-6.5%31.4%UnavailableUnavailableUnavailable
Operating margin-45066.7%-47577.9%-13013.4%-17034.3%-43164.6%-71884.0%
FCF margin-32529.6%-18500.0%-8926.8%-13209.3%-40170.7%-68068.0%
SBC / revenue6308.6%9107.8%1723.2%1886.2%3817.1%2904.0%
Current ratio1.69x1.92x2.51x5.80x13.11x1.22x
Revenue YoY growth5.2%-74.8%14.2%226.8%228.0%Unavailable
Net margin-39417.3%-42724.7%-11843.8%-16487.3%-42693.9%-79392.0%
R&D / revenue16260.5%19129.9%4975.5%5314.9%13437.8%31128.0%
CapEx / revenue896.3%72.7%41.8%295.1%1590.2%596.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SERA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 128036000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.